Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by PMV Pharmaceuticals, Inc. on June 6, 2024. The meeting was conducted exclusively via live webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals with the following outcomes:
- Proposal 1: Election of Directors
- Kirsten Flowers: Elected with 35,683,498 votes FOR, 656,260 WITHHELD, and 7,211,791 BROKER NON-VOTES.
- Carol Gallagher, Pharm.D.: Elected with 27,082,825 votes FOR, 9,256,933 WITHHELD, and 7,211,791 BROKER NON-VOTES.
- Both directors serve until the 2027 Annual Meeting.
- Proposal 2: Non-Binding Advisory Vote on Executive Compensation
- Approved with 34,452,101 votes FOR, 1,079,423 AGAINST, and 808,234 ABSTAIN.
- Broker non-votes totaled 7,211,791.
- The company will continue annual advisory votes until the 2028 annual meeting.
- Proposal 3: Ratification of Independent Auditor
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2024.
- Votes: 43,460,392 FOR, 90,902 AGAINST, and 255 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the definitive Proxy Statement (Schedule 14A) filed on April 24, 2024, for detailed executive compensation data.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2024 fiscal year.
- Note the significant number of broker non-votes (7,211,791) across all proposals, indicating shares held in street name where brokers lacked discretionary voting power.